USA flag logo/image

An Official Website of the United States Government

PROSTATE CANCER VACCINE BY SUPPRESSING Ii PROTEIN

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
53775
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43CA085100-01A1
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANTIGEN EXPRESS, INC.
ANTIGEN EXPRESS, INC. 100 BARBER AVE WORCESTER, MA 01606
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: PROSTATE CANCER VACCINE BY SUPPRESSING Ii PROTEIN
Agency: HHS
Contract: N/A
Award Amount: $191,744.00
 

Abstract:

DESCRIPTION: Suppressing the Ii protein by anti-sense oligonucleotides in MHC class Il-positive cancer cells creates a potent cancer cell vaccine. Presumably, additional determinants which are normally excluded in the ER by the Ii protein from the MHC class II antigenic peptide binding site, stimulate a potent and long lasting T helper cell response which guarantees (through dendritic cell 'licensing') a tumor-clearing T killer cell response. We have proved this point in two murine cancer models and identified the most active lead drug. We now focus on prostate cancer because there are no life savings therapies once tumor recurs in patients with an otherwise healthy immune system. Adequate tumor is available in 50 percent of patients at primary resection, and in all early during recurrence. Tumor is also then accessible to injection in situ with liposomes and immunoliposomes containing the lead drug. First, we have begun to validate Ii protein suppression methods in human prostate cancer cell lines (in anticipation of preparing cancer cell vaccines under Phase II). Second, we will optimize cell vaccine dose and dosing schedule in the murine RM-9 prostate cancer model, as we have done in two previous murine tumor models. Third, we will use the optimized cell vaccine regimen plus GM-CSF (and subsequently lL-2) to treat mice with established subcutaneous and orthotopic RM-9 tumors. Subsequent studies in Phase II will focus on the use of fresh human tissues, the inclusion of radiation in the treatment of advanced RM-9 tumors and a pre-IND conference with the FDA. PROPOSED COMMERCIAL APPLICATION: Tumor cell vaccine for prostate, breast, ovarian and colon cancer. In situ immunotherapy of metastates enhancement or dendritic cell immunotherapies for cancer.

Principal Investigator:

Robert E. Humphreys

Business Contact:


5087986683
ANTIGENEXP@AOL.COM
Small Business Information at Submission:

ANTIGEN EXPRESS, INC.
1 INNOVATION DR WORCESTER, MA 01605

EIN/Tax ID: 043208418
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No